Keefe, Bruyette & Woods analyst Ryan Lynch downgrades Hercules Capital (NYSE:HTGC) from Market Perform to Underperform and lowers the price target from $14.5 to $10.5.
Keefe, Bruyette & Woods analyst Ryan Lynch maintains Hercules Capital (NYSE:HTGC) with a Market Perform and raises the price target from $12.5 to $14.5.
Companies Reporting Before The Bell
• RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022.
• Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.
Hercules Capital, Inc. (NYSE: HTGC) is pleased to announce that its Board of Directors has declared a new supplemental cash distribution of $0.32 per share, to be distributed equally over four quarters beginning with an $0.08 per share distribution for the fourth quarter of 2022.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an
Hercules Capital (NYSE:HTGC) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.36 by 8.33 percent. This is a 18.18 percent increase over earnings of $0.33 per share from the
In the past month with the Russell 2000 index up roughly 7%, as compared to the S&P 500 index up nearly 4.8%, it is evident that small cap stocks are leading the charge in this bear market rally. The WisdomTree U.S.
Over the past 3 months, 4 analysts have published their opinion on Hercules Capital (NYSE:HTGC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.